CM310 for uncontrolled seasonal allergic rhinitis
The Efficacy and Safety of Humanized Antibody Targeting the Interleukin-4 Receptor Alpha Subunit (IL-4Rα) in Patients With Uncontrolled Seasonal Allergic Rhinitis Under Standard Treatment： A Randomized, Double-Blind, Placebo-controlled IIT Study
This trial will try CM310, a medicine that blocks the interleukin‑4 receptor, in people whose seasonal allergic rhinitis is not well controlled by current treatments.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Beijing Tongren Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06300203 on ClinicalTrials.gov |
What this trial studies
This is a Phase 2 interventional trial testing CM310, a monoclonal antibody that targets the interleukin‑4 receptor, in patients with uncontrolled seasonal allergic rhinitis. Participants will receive CM310 or a placebo and be followed for changes in nasal and ocular symptoms as well as safety measures. The trial is conducted at Beijing Tongren Hospital with voluntary informed consent and standard exclusion criteria to protect participant safety. Findings will help determine whether CM310 reduces symptom burden and improves quality of life compared with placebo.
Who should consider this trial
Good fit: People with seasonal allergic rhinitis whose symptoms remain uncontrolled despite usual treatments and who can attend study visits at Beijing Tongren Hospital are the intended participants.
Not a fit: People with well‑controlled allergy symptoms, perennial or non‑allergic rhinitis, or those unable to travel to the Beijing site are unlikely to receive benefit from this trial.
Why it matters
Potential benefit: If successful, CM310 could reduce nasal and eye allergy symptoms and improve daily functioning for people with uncontrolled seasonal allergic rhinitis.
How similar studies have performed: Other drugs that block the IL‑4/IL‑13 pathway have shown benefit in related allergic conditions, offering a supportive rationale though CM310 itself is a newer agent with limited prior data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Voluntarily sign the informed consent form. Exclusion Criteria: * Have any condition that are not suitable for participating in this study.
Where this trial is running
Beijing, Beijing Municipality
- Beijing Tongren Hospital, Capital Medical University — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Luo Zhang
- Email: dr.luozhang@139.com
- Phone: +86-13910830399
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.